Member Exclusive News

FDA approves first-in-class treatment for rare adrenal tumors

The US FDA has approved Progenics Pharmaceuticals’ Adzera®, a first-in-class treatment for two rare adrenal tumors: pheochromocytoma and paraganglioma.

Go to the profile of Jasmine Harris
Aug 02, 2018

Please sign in or register for FREE

No comments yet.